Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 10/20 | 0.36 |
| ▸ | FEN1 | P39748 | 10/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859645 | 0.69 | F10 (0.63) | F10FPR2FPR1 | |
| SCHEMBL6853311 | 0.68 | F10 (0.42) | ALOX5APFEN1F10 | |
| SCHEMBL7520638 | 0.67 | FPR1 (0.35) | ALOX5APFEN1F10FPR2FPR1 | |
| SCHEMBL6859578 | 0.66 | ALDH1A1 (0.36) | F10FPR2TDP2 | |
| SCHEMBL3831543 | 0.61 | ALOX5AP (0.60) | ALOX5APFEN1 | |
| SCHEMBL13148214 | 0.61 | KMT2A (0.48) | — | |
| Fluorobenzene SCHEMBL27495586 | 0.58 | DRD2 (0.47) | — | |
| SCHEMBL29519663 | 0.58 | GABRG2 (0.43) | — | |
| SCHEMBL1792671 | 0.58 | ACLY (0.53) | ALOX5APFEN1ACLY | |
| SCHEMBL20340238 | 0.58 | CDC7 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790845-B2 | HAVING AN ATTACHED NON-AROMATIC HETEROCYCLIC RING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | TFPI, F11, F12 | ALOX5AP 3796/4885FEN1 933/4885F10 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.